Putnam Perspective: Orphan Drugs »

Putnam Associates reports on how orphan diseases represent areas of significant unmet need. There are approximately 7,000 recognized orphan diseases yet only about 200 approved products...

Boston’s Third Rock Ventures Closes $516 Fund, Boston Globe 3/16/13 »

Third Rock Ventures, a Boston venture capital firm, has closed a new $516 million fund and plans to begin investing in innovative life-sciences start-ups in...

Genzyme Advances MS Drug Business »

Is this city big enough for two multiple sclerosis drug makers?  We're about to find out.  With Genzyme’s disclosure...

Product Launch Strategy »

Situation

A pharmaceutical company anticipated market approval for a drug that served patients in a highly competitive category of infectious disease. The...